ARCHIVES

Funding Opportunities: NCI Offers Funds To Develop, Validate Mouse Models

This article is from The Cancer Letter archive.

Vol. 24 No. 44 | November 20, 1998

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Claim “Major Finding” In Treatment Of Soft Tissue Sarcoma With Three Modalities; 93% Survival

October 9, 1981

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

December 26, 2014

Compliance Grants Awarded, Contract Pending On Differences In Black/White Survival

November 19, 1982

FDA Approves Lilly’s Alimta For Metastatic NSCLC

August 27, 2004

Advisors Approve New Grant Programs In Breast Pre-Malignancy, Lung Inflammation

November 17, 2006

NCI Cooperative Group, Cancer Center Trials Listed

September 28, 2007